Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rainier: OGX-427 + Gem/Nab in Metastatic Pancreatic Cancer
NCT01844817Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Sep 2013
- Primary completion
- Mar 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of apatorsen in pancreatic cancer (PC), sponsored by SCRI Development Innovations. Started Sep 2013; status: completed.
02
Drugs
apatorsen
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT01844817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01844817.